Cargando…

Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation

Lung cancer is currently the most prevalent cause of cancer mortality due to late diagnosis and lack of curative therapies. Docetaxel (Dtx) is clinically proven as effective, but poor aqueous solubility and non-selective cytotoxicity limit its therapeutic efficacy. In this work, a nanostructured lip...

Descripción completa

Detalles Bibliográficos
Autores principales: Idris, Auni Hamimi, Che Abdullah, Che Azurahanim, Yusof, Nor Azah, Asmawi, Azren Aida, Abdul Rahman, Mohd Basyaruddin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222445/
https://www.ncbi.nlm.nih.gov/pubmed/37242561
http://dx.doi.org/10.3390/pharmaceutics15051319
_version_ 1785049700404035584
author Idris, Auni Hamimi
Che Abdullah, Che Azurahanim
Yusof, Nor Azah
Asmawi, Azren Aida
Abdul Rahman, Mohd Basyaruddin
author_facet Idris, Auni Hamimi
Che Abdullah, Che Azurahanim
Yusof, Nor Azah
Asmawi, Azren Aida
Abdul Rahman, Mohd Basyaruddin
author_sort Idris, Auni Hamimi
collection PubMed
description Lung cancer is currently the most prevalent cause of cancer mortality due to late diagnosis and lack of curative therapies. Docetaxel (Dtx) is clinically proven as effective, but poor aqueous solubility and non-selective cytotoxicity limit its therapeutic efficacy. In this work, a nanostructured lipid carrier (NLC) loaded with iron oxide nanoparticles (IONP) and Dtx (Dtx-MNLC) was developed as a potential theranostic agent for lung cancer treatment. The amount of IONP and Dtx loaded into the Dtx-MNLC was quantified using Inductively Coupled Plasma Optical Emission Spectroscopy and high-performance liquid chromatography. Dtx-MNLC was then subjected to an assessment of physicochemical characteristics, in vitro drug release, and cytotoxicity. Dtx loading percentage was determined at 3.98% w/w, and 0.36 mg/mL IONP was loaded into the Dtx-MNLC. The formulation showed a biphasic drug release in a simulated cancer cell microenvironment, where 40% of Dtx was released for the first 6 h, and 80% cumulative release was achieved after 48 h. Dtx-MNLC exhibited higher cytotoxicity to A549 cells than MRC5 in a dose-dependent manner. Furthermore, the toxicity of Dtx-MNLC to MRC5 was lower than the commercial formulation. In conclusion, Dtx-MNLC shows the efficacy to inhibit lung cancer cell growth, yet it reduced toxicity on healthy lung cells and is potentially capable as a theranostic agent for lung cancer treatment.
format Online
Article
Text
id pubmed-10222445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102224452023-05-28 Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation Idris, Auni Hamimi Che Abdullah, Che Azurahanim Yusof, Nor Azah Asmawi, Azren Aida Abdul Rahman, Mohd Basyaruddin Pharmaceutics Article Lung cancer is currently the most prevalent cause of cancer mortality due to late diagnosis and lack of curative therapies. Docetaxel (Dtx) is clinically proven as effective, but poor aqueous solubility and non-selective cytotoxicity limit its therapeutic efficacy. In this work, a nanostructured lipid carrier (NLC) loaded with iron oxide nanoparticles (IONP) and Dtx (Dtx-MNLC) was developed as a potential theranostic agent for lung cancer treatment. The amount of IONP and Dtx loaded into the Dtx-MNLC was quantified using Inductively Coupled Plasma Optical Emission Spectroscopy and high-performance liquid chromatography. Dtx-MNLC was then subjected to an assessment of physicochemical characteristics, in vitro drug release, and cytotoxicity. Dtx loading percentage was determined at 3.98% w/w, and 0.36 mg/mL IONP was loaded into the Dtx-MNLC. The formulation showed a biphasic drug release in a simulated cancer cell microenvironment, where 40% of Dtx was released for the first 6 h, and 80% cumulative release was achieved after 48 h. Dtx-MNLC exhibited higher cytotoxicity to A549 cells than MRC5 in a dose-dependent manner. Furthermore, the toxicity of Dtx-MNLC to MRC5 was lower than the commercial formulation. In conclusion, Dtx-MNLC shows the efficacy to inhibit lung cancer cell growth, yet it reduced toxicity on healthy lung cells and is potentially capable as a theranostic agent for lung cancer treatment. MDPI 2023-04-22 /pmc/articles/PMC10222445/ /pubmed/37242561 http://dx.doi.org/10.3390/pharmaceutics15051319 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Idris, Auni Hamimi
Che Abdullah, Che Azurahanim
Yusof, Nor Azah
Asmawi, Azren Aida
Abdul Rahman, Mohd Basyaruddin
Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation
title Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation
title_full Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation
title_fullStr Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation
title_full_unstemmed Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation
title_short Nanostructured Lipid Carrier Co-Loaded with Docetaxel and Magnetic Nanoparticles: Physicochemical Characterization and In Vitro Evaluation
title_sort nanostructured lipid carrier co-loaded with docetaxel and magnetic nanoparticles: physicochemical characterization and in vitro evaluation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222445/
https://www.ncbi.nlm.nih.gov/pubmed/37242561
http://dx.doi.org/10.3390/pharmaceutics15051319
work_keys_str_mv AT idrisaunihamimi nanostructuredlipidcarriercoloadedwithdocetaxelandmagneticnanoparticlesphysicochemicalcharacterizationandinvitroevaluation
AT cheabdullahcheazurahanim nanostructuredlipidcarriercoloadedwithdocetaxelandmagneticnanoparticlesphysicochemicalcharacterizationandinvitroevaluation
AT yusofnorazah nanostructuredlipidcarriercoloadedwithdocetaxelandmagneticnanoparticlesphysicochemicalcharacterizationandinvitroevaluation
AT asmawiazrenaida nanostructuredlipidcarriercoloadedwithdocetaxelandmagneticnanoparticlesphysicochemicalcharacterizationandinvitroevaluation
AT abdulrahmanmohdbasyaruddin nanostructuredlipidcarriercoloadedwithdocetaxelandmagneticnanoparticlesphysicochemicalcharacterizationandinvitroevaluation